Does the media prefer BEAM or NTLA?

In the previous week, Beam Therapeutics had 5 more articles in the media than Intellia Therapeutics. MarketBeat recorded 6 mentions for Beam Therapeutics and 1 mentions for Intellia Therapeutics. Beam Therapeutics' average media sentiment score of 0.81 beat Intellia Therapeutics' score of 0.61 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SYRE or NTLA?

In the previous week, Spyre Therapeutics had 9 more articles in the media than Intellia Therapeutics. MarketBeat recorded 10 mentions for Spyre Therapeutics and 1 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.61 beat Spyre Therapeutics' score of 0.32 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Intellia Therapeutics (NTLA) Competitors

$15.50 +0.25 (+1.64%)

Closing price 04:00 PM Eastern

Extended Trading

$15.57 +0.07 (+0.47%)

As of 08:00 PM Eastern

Compare

NTLA vs. BEAM, CRSP, EDIT, SYRE, and PRAX

Should you buy Intellia Therapeutics stock or one of its competitors? MarketBeat compares Intellia Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Intellia Therapeutics include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Spyre Therapeutics (SYRE), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

How does Intellia Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Beam Therapeutics has a net margin of -39.66% compared to Intellia Therapeutics' net margin of -597.04%. Beam Therapeutics' return on equity of -29.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

In the previous week, Beam Therapeutics had 5 more articles in the media than Intellia Therapeutics. MarketBeat recorded 6 mentions for Beam Therapeutics and 1 mentions for Intellia Therapeutics. Beam Therapeutics' average media sentiment score of 0.81 beat Intellia Therapeutics' score of 0.61 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	24.96	-$79.99M	-$0.68	N/A
Intellia Therapeutics	$67.67M	32.00	-$412.69M	-$3.54	N/A

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Beam Therapeutics presently has a consensus target price of $46.83, suggesting a potential upside of 38.15%. Intellia Therapeutics has a consensus target price of $20.46, suggesting a potential upside of 31.98%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Beam Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

Summary

Beam Therapeutics beats Intellia Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Intellia Therapeutics compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

In the previous week, Intellia Therapeutics had 1 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 1 mentions for Intellia Therapeutics and 0 mentions for CRISPR Therapeutics. Intellia Therapeutics' average media sentiment score of 0.61 beat CRISPR Therapeutics' score of 0.59 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CRISPR Therapeutics	Positive
Intellia Therapeutics	Positive

CRISPR Therapeutics currently has a consensus target price of $67.78, indicating a potential upside of 26.57%. Intellia Therapeutics has a consensus target price of $20.46, indicating a potential upside of 31.98%. Given Intellia Therapeutics' higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

Intellia Therapeutics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,471.48	-$581.60M	-$6.22	N/A
Intellia Therapeutics	$67.67M	32.00	-$412.69M	-$3.54	N/A

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

Intellia Therapeutics has a net margin of -597.04% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

Summary

Intellia Therapeutics beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to Editas Medicine?

Intellia Therapeutics (NASDAQ:NTLA) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Editas Medicine has a net margin of -281.59% compared to Intellia Therapeutics' net margin of -597.04%. Intellia Therapeutics' return on equity of -57.47% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Editas Medicine	-281.59%	-677.39%	-58.25%

Intellia Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market.

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Editas Medicine has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	32.00	-$412.69M	-$3.54	N/A
Editas Medicine	$40.52M	6.77	-$160.06M	-$1.23	N/A

In the previous week, Intellia Therapeutics had 1 more articles in the media than Editas Medicine. MarketBeat recorded 1 mentions for Intellia Therapeutics and 0 mentions for Editas Medicine. Intellia Therapeutics' average media sentiment score of 0.61 beat Editas Medicine's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Intellia Therapeutics	Positive
Editas Medicine	Neutral

Intellia Therapeutics currently has a consensus price target of $20.46, suggesting a potential upside of 31.98%. Editas Medicine has a consensus price target of $5.40, suggesting a potential upside of 92.86%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Intellia Therapeutics beats Editas Medicine on 10 of the 17 factors compared between the two stocks.

How does Intellia Therapeutics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Spyre Therapeutics has a beta of 3.05, suggesting that its stock price is 205% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Spyre Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,414.70	-$155.20M	-$2.08	N/A
Intellia Therapeutics	$67.67M	32.00	-$412.69M	-$3.54	N/A

In the previous week, Spyre Therapeutics had 9 more articles in the media than Intellia Therapeutics. MarketBeat recorded 10 mentions for Spyre Therapeutics and 1 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.61 beat Spyre Therapeutics' score of 0.32 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -597.04%. Spyre Therapeutics' return on equity of -42.88% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

Spyre Therapeutics currently has a consensus price target of $95.83, indicating a potential upside of 11.12%. Intellia Therapeutics has a consensus price target of $20.46, indicating a potential upside of 31.98%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

Summary

Spyre Therapeutics beats Intellia Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Intellia Therapeutics compare to Praxis Precision Medicines?

Intellia Therapeutics (NASDAQ:NTLA) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Intellia Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market.

Praxis Precision Medicines has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -597.04%. Praxis Precision Medicines' return on equity of -43.02% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Praxis Precision Medicines has lower revenue, but higher earnings than Intellia Therapeutics. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	32.00	-$412.69M	-$3.54	N/A
Praxis Precision Medicines	$8.55M	1,007.40	-$303.27M	-$13.37	N/A

In the previous week, Praxis Precision Medicines had 7 more articles in the media than Intellia Therapeutics. MarketBeat recorded 8 mentions for Praxis Precision Medicines and 1 mentions for Intellia Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.66 beat Intellia Therapeutics' score of 0.61 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Intellia Therapeutics presently has a consensus price target of $20.46, indicating a potential upside of 31.98%. Praxis Precision Medicines has a consensus price target of $566.21, indicating a potential upside of 83.28%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Praxis Precision Medicines beats Intellia Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Intellia Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTLA vs. The Competition

Export

Metric	Intellia Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.13B	$3.49B	$6.54B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-4.38	20.50	25.39	23.96
Price / Sales	32.00	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	2.67	8.26	10.76	6.41
Net Income	-$412.69M	$23.91M	$3.56B	$337.14M
7 Day Performance	1.97%	3.05%	1.37%	-0.48%
1 Month Performance	23.02%	2.40%	0.81%	0.49%
1 Year Performance	61.96%	56.35%	30.53%	28.16%

Intellia Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTLA Intellia Therapeutics	3.1428 of 5 stars	$15.50 +1.6%	$20.46 +32.0%	+65.2%	$2.13B	$67.67M	N/A	600
BEAM Beam Therapeutics	3.2695 of 5 stars	$35.53 +4.1%	$46.83 +31.8%	+98.7%	$3.66B	$139.74M	N/A	510	Positive News Gap Up
CRSP CRISPR Therapeutics	3.3565 of 5 stars	$54.36 +0.5%	$67.78 +24.7%	+18.5%	$5.24B	$3.51M	N/A	460
EDIT Editas Medicine	2.6492 of 5 stars	$2.80 +4.1%	$5.40 +92.9%	+31.4%	$274.15M	$40.52M	N/A	230
SYRE Spyre Therapeutics	1.6831 of 5 stars	$100.32 +13.6%	$94.17 -6.1%	+561.1%	$8.71B	$890K	N/A	73	Analyst Forecast Insider Trade Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTLA) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intellia Therapeutics (NTLA) Competitors

NTLA vs. BEAM, CRSP, EDIT, SYRE, and PRAX

How does Intellia Therapeutics compare to Beam Therapeutics?

Summary

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Summary

How does Intellia Therapeutics compare to Editas Medicine?

Summary

How does Intellia Therapeutics compare to Spyre Therapeutics?

Summary

How does Intellia Therapeutics compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA vs. The Competition

Intellia Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intellia Therapeutics (NTLA) Competitors

NTLA vs. BEAM, CRSP, EDIT, SYRE, and PRAX

How does Intellia Therapeutics compare to Beam Therapeutics?

Is BEAM or NTLA more profitable?

Does the media prefer BEAM or NTLA?

Which has more volatility and risk, BEAM or NTLA?

Which has stronger valuation and earnings, BEAM or NTLA?

Do insiders & institutionals hold more shares of BEAM or NTLA?

Do analysts prefer BEAM or NTLA?

Summary

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Does the media favor CRSP or NTLA?

Do analysts prefer CRSP or NTLA?

Which has preferable valuation & earnings, CRSP or NTLA?

Do institutionals and insiders hold more shares of CRSP or NTLA?

Which has more risk & volatility, CRSP or NTLA?

Is CRSP or NTLA more profitable?

Summary

How does Intellia Therapeutics compare to Editas Medicine?

Is NTLA or EDIT more profitable?

Which has more risk and volatility, NTLA or EDIT?

Do insiders & institutionals believe in NTLA or EDIT?

Which has stronger valuation and earnings, NTLA or EDIT?

Does the media favor NTLA or EDIT?

Do analysts rate NTLA or EDIT?

Summary

How does Intellia Therapeutics compare to Spyre Therapeutics?

Which has more volatility and risk, SYRE or NTLA?

Do institutionals and insiders believe in SYRE or NTLA?

Which has preferable valuation & earnings, SYRE or NTLA?

Does the media refer more to SYRE or NTLA?

Is SYRE or NTLA more profitable?

Do analysts rate SYRE or NTLA?

Summary

How does Intellia Therapeutics compare to Praxis Precision Medicines?

Which has more volatility and risk, NTLA or PRAX?

Is NTLA or PRAX more profitable?

Which has higher valuation & earnings, NTLA or PRAX?

Does the media prefer NTLA or PRAX?

Do analysts recommend NTLA or PRAX?

Do insiders and institutionals believe in NTLA or PRAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA vs. The Competition

Intellia Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools